Popvax

PopVax is an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using computational protein design. Our first vaccine is a next-generation COVID-19 booster which will enter a first-in-human Phase I clinical trial in the U.S. early next year – this vaccine is intended to broaden protection against both current and predicted future SARS-CoV-2 variants, reducing the possibility of a new mutation in the virus suddenly causing another massive wave of infection. We are now a team of 70+ across our computational design, machine learning, molecular & cell biology, immunology, mRNA delivery, analytical method development, GMP production, quality, and regulatory teams, all of which are hiring. Our experimental work is based at the RNA Foundry, PopVax’s integrated R&D and GMP-capable clinical dose production facility in Hyderabad. Our work to date has been funded primarily via project agreements with the Bill & Melinda Gates Foundation and Vitalik Buterin's public health & biosecurity organization Balvi. Over the next decade, our mission is to develop and distribute vaccines that save one million lives each year across the world that would otherwise be lost to infectious diseases.